Ministry of Health and Long-Term Care

Ontario Public Drug Programs

Drug Submission Status

Generic Name:	glatiramer acetate		
Brand Name:	Copaxone		
Strength:	20mg/1mL pre-filled syringe		
Manufacturer:	Teva Pharmaceutical Industries Ltd.		
Indication:	Clinically Isolated Syndrome (CIS), after a first		
indication:	demyelinating event		
Rapid Review:	Not requested		

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	29/07/2009	13/11/2009	EO decision rendered	Funding available through the Exceptional Access Program (EAP)

Rapid Review:

Details of the Rapid Review process can be found at: www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html

Review Status:

- Screening Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration A
 recommendation was made by the CED, however the manufacturer has submitted or will be
 submitting additional information.
- o Committee to Evaluate Drugs (CED) review completed A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Decision:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision can be found at: www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html

Updated: January 7, 2011



